Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morphine-neostigmine vs Secretin Provocation MRCP in Healthy Volunteers
NCT01134848Phase 4
Key facts
- Status
- Completed
- Start
- Jan 2009
- Primary completion
- Feb 2010
- Countries
- 1
- Sponsor
- University of Nottingham
- Modality
- Small Molecules
- Drugs
- morphineneostigmine
- Conditions
- sphincter of Oddi dysfunction (SOD)
01
Overview
Phase 4, randomised, double-blind trial of morphine and neostigmine in sphincter of Oddi dysfunction (SOD) (2 arms), sponsored by University of Nottingham. Primary endpoints: Serum amylase, Serum lipase and 1 more. Started Jan 2009; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Morphine-neostigmine
Morphine 10mg IM + Neostigmine 1mg IM
Secretin
Secretin 1 unit/kg IV
03
Who it enrols
Healthy age and sex matched volunteers with no history of chronic abdominal pain, abdominal surgery, or GI motility disorders.
04
Endpoints
Primary
Serum amylase
Serum lipase
Liver function tests
Secondary
Pancreatic duct diameter
Pancreatic duct length
Common bile duct diameter
Gallbladder volume
Beyond the preview
Go deeper on NCT01134848.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01134848.